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ABSTRACT
We aimed to investigate the feasibility of simultaneously sparing the hippocampus and hypothalamic-hypophysial axis (HHA) during 
whole brain radiotherapy (WBRT) using helical tomotherapy. Images of totally 12 patients were analyzed. Hippocampi and HHA were 
delineated according to available guidelines. First, radiotherapy plans were analyzed according to dose constraints of the Radiation 
Therapy Oncology Group-0933 for 30 Gy (3 Gy/fr). Second, dose constraints were decreased by 1/6 to simulate the 25 Gy prophy-
lactic cranial irradiation practice. The mean D98% and D2% was 25.9±0.85 Gy and 35.0±1.32 Gy, and 21.4±0.40 Gy and 30.5±1.33 
Gy for planning target volumes in the original and modified protocol plans, respectively. The D100% and Dmax for the hippocampus was 
8.1±0.47 Gy and 15.7±0.84 Gy in the original and 7.1±0.68 Gy and 13.2±1.08 Gy in the modified protocol, respectively. The mean 
doses for the hypothalamus and hypophysis was 12.6±0.76 Gy and 11.4±1.22 Gy in the original and 10.8±1.38 Gy and 9.8±1.50 Gy 
in the modified plans, respectively. This study demonstrated the feasibility of sparing the hippocampus and HHA simultaneously during 
WBRT with helical tomotherapy regarding target dose coverage and dose constraints suggested by the literature.
Keywords: Hippocampus, Hypothalamic-hypophysis axis sparing whole brain radiotherapy, Prophylactic cranial radiotherapy
ÖZET
Tüm Beyin Radyoterapisi Esnasında Hipokampüs ve Hipotalamo-Hipofizer Aksın Korunabilirliği: Dozimetrik Çalışma
Tüm beyin radyoterapisi (TBR) esnasında hipokampüs ve hipotalamo-hipofizer aksın (HHA) eşzamanlı olarak helikal tomoterapi 
yardımıyla korunabilirliğini araştırmayı amaçladık. Toplam 12 hastanın görüntüleri analiz edilmiştir. Hipokampüs ve HHA mevcut re-
hberlere göre konturlanmıştır. İlk olarak hastalar 30 Gy (3 Gy/fr) için Radiation Therapy Oncology Group-0933 doz sınırlamalarına 
göre analiz edilmiştir. İkinci olarak ise doz kısıtlamaları 1/6 oranında azaltılarak 25 Gy’lik proflaktik kranial radyoterapi pratiği simüle 
edilmiştir. Orjinal ve modifiye edilen protokollerde ortalama D%98 ve D%2 sırasıyla 25.9±0.85 Gy ve 35.0±1.32 Gy; 21.4±0.40 Gy ve 
30.5±1.33 Gy olarak bulunmuştur. Orjinal planda hipokampüs için D100% ve Dmax sırasıyla 8.1±0.47 Gy ve 15.7±0.84 Gy iken modi-
fiye planda 7.1±0.68 Gy ve 13.2±1.08 Gy olarak tespit edilmiştir. Orjinal plandaki ortalama hipotalamus ve hipofiz dozları 12.6±0.76 
Gy ve 11.4±1.22 Gy; modifiye planda ise 10.8±1.38 Gy ve 9.8±1.50 Gy olarak bulunmuştur. Bu çalışma literatür tarafından önerilen 
doz sınırlamaları ve hedef doz sarımı açısından helical tomoterapiyle hipokampüs ve HHA’ın aynı anda korunabilir olduğunu gösterir 
niteliktedir. 
Anahtar Kelimeler: Hipokampüs, Hipotalamo-hipofizer aks koruyucu tüm beyin radyoterapisi, Proflaktik kranial radyoterapi
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INTRODUCTION
Prophylactic cranial irradiation (PCI) is an inte-
gral part of standard treatment algorithms in some 
malignancies including small-cell lung carcinoma 
and acute lymphoblastic leukemia.1-4 The main 
rationale underlying the use of PCI in patients is 
the well-recognized limited permeability of the 
blood-brain-barrier to many chemotherapeutics, 
rendering the brain a sanctuary site for malignant 
cells.5 In this setting, PCI decreases brain relapses 
by eradication of occult tumor cells, which cannot 
be determined by current diagnostic tools. Thus, 
PCI enhances the overall survival rates with rela-
tively lower radiotherapy doses compared the dose 
utilized for palliation of brain metastases.6 Despite 
these advantages of PCI, there is a significant risk 
of deterioration of neurocognitive functions (NCF) 
according to the objective baseline measurements, 
which is the major limitation against its usage.7 
Radiation-induced hippocampal injury is the most 
established cause of neurocognitive dysfunction in 
patients treated with PCI and/or palliative whole 
brain radiotherapy (WBRT); this is related to the 
injury of neural progenitor cells in the subventricu-
lar zone and hippocampus in addition to damage 
of the vascular structure and glial precursors.8-13 
In this regard, hippocampus-sparing WBRT has 
repeatedly been demonstrated to be safe and use-
ful in sparing NCF with no sacrifice of potentially 
microscopically involved brain sites.14-16
Given the separated parts of the brain with sophis-
ticated interconnections, it seems reasonable to as-
sume that other parts of the brain can contribute 
to the NCF as well as the master neurocognitive 
organ, the hippocampus.17 Recent studies report 
that a limited post-development neurogenesis can 
occur in other sides of the brain including stria-
tum, spinal cord, and neurocortex as well as the 
hypothalamus.18  The hypothalamus is responsible 
for the maintenance of homeostatic functions and 
quality of life (QOL). Therefore the preservation of 
the hypothalamic-hypophysial axis (HHA), known 
as the master of the neuroendocrine system, can re-
duce the risks of both neuroendocrine dysfunction 
and NCF particularly in groups of patients with 
longer survival expectations.19-22  
Radiation-induced HHA dysfunction has been de-
termined to be a dose- and time- dependent adverse 
event, but the radiation doses causing impaired 
QoL as a result of HHA-related damage has not yet 
been determined.23,24  On the other hand, some sug-
gestions about the dose constraints of hippocam-
pus were offered: <7.3 Gy to 40% of bilateral hip-
pocampi 14 and a maximum dose (Dmax) of 9 Gy 
to 100% of the hippocampi.25 Therefore, it is logi-
cal to anticipate that sparing of both the hippocam-
pi and HHA can be a more effective approach for 
maximum maintenance of the NCF, rather than the 
hippocampus-sparing-WBRT alone in patients un-
dergoing PCI. Enlightened by the available litera-
ture, we evaluated the feasibility of simultaneously 
sparing hippocampus + hypothalamus + hypophy-
sis (3HS) which can be abbreviated as 3HS-WBRT 
in patients undergoing WBRT.
PATIENTS AND METHODS
Contouring
Datasets including planning computerized tomog-
raphy (CT) fused with T1-weighted post-contrast 
axial MRI images (slices 1.5 mm thick) of 12 
patients accessible on the Picture Archiving and 
Communication System were selected. The CT 
images were obtained 120 kVp, 400 mA, and 1.25 
mm thickness. Hippocampi were delineated ac-
cording to the Radiation Therapy Oncology Group 
(RTOG)-093326, and hippocampal avoidance zones 
were uniformly defined by 5 mm expansion in all 
directions from the hippocampi.
The hypothalamus was delineated by utilizing the 
method described by Elson et al27 and additional 
MRI atlases.28 In brief, the most cranial contouring 
section corresponded to the anterior commissure, 
which is located at the medial sides of the third 
ventricle (Figure 1). The most inferior section of 
the contour was 1.5 mm (1 axial slice) superior to 
the slice where the optic chiasm emerges first.  The 
anterior side of the third ventricle and interpedun-
cular fossa constituted the anterior and posterior 
boundaries, respectively. Lastly, either the optic 
white matter or internal capsule was defined as the 
lateral border of the hypothalamus. The hypophy-
sis was delineated as the concavity within the sphe-
noid bone, sella tursica, which is located laterally 
between the cavernous sinuses, the hypothalamus 
and optic chiasm cranially. As recommended, the 
bone window was utilized for this purpose as the 
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most appropriate CT mode for delineation of the 
hypophysis. A uniform additional 5 mm was added 
to both the hypothalamus and hypophysis in all 
directions to constitute the planning organ at risk 
volumes. The organs at risk constituted the lenses, 
globes, optic nerves, and chiasms were delineated 
according to the accessible contouring guidelines.29
The clinical target volume was the whole brain to 
second cervical vertebra and 2 mm was added to 
create the planning target volume (PTV). However, 
the final PTV was defined by subtracting the plan-
ning organ at risk volumes of the hippocampus and 
HHA from the PTV. 
Treatment Planning and Procedure 
Although our institutional PCI protocol mandates 
a total dose of 25 Gy in 10 fractions, we also per-
formed alternative plans with 30 Gy in 10 fractions 
for each patient utilizing helical tomotherapy (HT) 
Accuray planning system (Tomo HDA, version 
2.1.2) to simulate palliative WBRT studies. The 
dose limitations of the PTV and organs at risk have 
been identified in accordance with the RTOG 0933 
protocol 26 and a modified dose limitation was de-
scribed by reducing all the recommended doses in 
the trial by 5/6, in the view of the 25 Gy of PCI. 
Planning was performed using the 1.048-cm wide 
field with a pitch of 0.221 and a modulation fac-
tor of 5 and dose calculation grid of 0.203 cm x 
0.203 cm. All the dose specifications are shown 
in Table 1. Although the present study was not a 
comparison study, the mean homogeneity index 
(HI) defined as the measure of the steepness of 
the target, was also calculated to compare our re-
sults with similar studies. The HI was defined as 
[(D2% - D98%)/Dmedian], where a value closer to 
0 is associated with optimal plan according to the 
International Commission on Radiation Units and 
Measurements.30
Figure 1. Dose color wash images of a patient receiving 25 Gy of prophylactic cranial irradiation dose utilizing by helical tomotherapy; 
A. axial section of helical tomotherapy plan with the delineations of hippocampus (dark blue) and hypothalamus (brown); B. sagit-
tal section demonstrating the hippocampus; C. coronal section radiotherapy plan demonstrating the hippocampus (dark blue) and 
hypothalamus (brown); D. axial section plan demonstrating the hippocampus bilaterally and hypophysis (white arrow) in the midline; 
E. sagittal section plan demonstrating the preservation of hypothalamus (brown) and hypophysis (green, white arrow); F. coronal sec-
tion plan demonstrating the hypophysis (white arrow) in the midline
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Statistical Analysis
All calculations and statistical tests were per-
formed utilizing IBM SPSS 17.0 software (SPSS, 
Inc., Chicago, IL, USA). With respect to dosimetric 
evaluation, continuous variables were expressed as 
mean (± SD)
RESULTS
The compliance criteria, limitations of organs at 
risk which were based on RTOG-0933 and the 
modified protocol are demonstrated in Table 1. The 
average dosimetric values in 12 patients are shown 
in Table 2. 
PTV, Homogeneity Index, and Delivery Time
All the plans met the acceptance criteria. The mean 
D98% and D2% was 25.9 ± 0.85 Gy and 35.0 ± 1.32 
Gy, and 21.4 ± 0.40 Gy and 30.5 ± 1.33 Gy for 
PTV in the protocol and modified protocol plans, 
respectively (Table 2). The HI was 0.30 ± 0.07 in 
both of the protocols. The mean delivery time was 
31.8 minutes ± 1.81.
Volumes and Dosimetry of the Hippocampus, 
Hypothalamus and Hypophysis
The mean volumes of the hippocampus, hypothala-
mus, and hypophysis were 5.6 cm3 ± 1.82, 0.7 cm3 
± 0.30 and 0.5 cm3 ± 0.16, respectively. The mini-
mum (D100%) and maximum doses (Dmax) for the 
hippocampus were 8.1 ± 0.47 Gy and 15.7 ± 0.84 
Gy in the protocol and 7.1 ± 0.68 Gy and 13.2 ± 
1.08 Gy in the modified protocol, respectively. The 
mean doses for the hypothalamus and hypophysis 
were 12.6 ± 0.76 Gy and 11.4 ± 1.22 Gy in the pro-
tocol plan and 10.8 ± 1.38 Gy and 9.8 ± 1.50 Gy, in 
the modified plan, respectively.
DISCUSSION
To the best of our knowledge, this dosimetric study 
confirmed the feasibility of simultaneous protec-
tion of the hippocampus and HHA without sacri-
ficing PTV coverage by utilizing HT; the only cost 
was relatively longer treatment times (31.8 min-
utes ± 1.81) than that for the standard WBRT.
Maintenance of NCF as a major component of QoL 
has gradually gained increasing consideration in 
patients with cancer undergoing PCI, because of 
the significantly increased WBRT-related toxicity 
rates in long-term survivors of PCI in the pres-
ence of more effective systemic and loco-regional 
treatment options.31,32 Studies indicate that unilat-
eral or bilateral hippocampal damage is related to 
neurocognitive disorders, particularly in memory 
and learning, and hippocampal-sparing techniques 
have been suggested for either WBRT or partial ra-
diotherapy of the brain in order to spare NCF.26,33 
Although hippocampus-sparing WBRT has been 
the most utilized approach for this purpose, further 
complications such as fatigue, sleeping disorders, 
reduced muscle mass, low energy, and hormonal 
deficiencies can still alter the NCF, and therefore, 
the patients’ overall QoL in a negative manner.32 
Table 1. Dose specifications
Organ Per protocol Acceptable Modified protocol Acceptable
PTV D98% ≥25.0 Gy D98% <25.0 Gy D98% ≥20.80Gy D98% <20.8.0 Gy
 D2%  ≤37.5 Gy D2%  >37.5 Gy, ≤40 Gy D2%  ≤31.25 Gy D2%  >31.25 Gy, ≤33.3 Gy
Hippocampus D100% ≤9 Gy D100%  ≤10 Gy D100%  ≤7.5 Gy D100%  ≤9 Gy
 Dmax  ≤16 Gy Dmax  ≤17 Gy Dmax ≤13.3 Gy Dmax  ≤17 Gy
Hypothalamus Dmean ≤12 Gy Dmean ≤14 Gy Dmean ≤10 Gy Dmean ≤14 Gy
Pituitary gland Dmean ≤12 Gy Dmean ≤14 Gy Dmean ≤10 Gy Dmean ≤14 Gy
Optic chiasm and nerves Dmax  ≤37.5 Gy Dmax  ≤37.5 Gy Dmax  ≤37.5 Gy Dmax  ≤37.5 Gy
Lens Dmax  ≤5Gy Dmax  ≤10 Gy Dmax  ≤5Gy Dmax  ≤10 Gy
Abbreviations: PTV= planning target volume; D98%= the dose which %98 of the target volume receives;  D2%= the dose which 2% of the target volume 
receives; D100%= minimum dose; Dmax= maximum dose; Dmean= mean dose
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In this context, considering the neuroendocrine and 
homeostatic functions of HHA, as a master organ, 
3HS-WBRT can be superior for further sparing 
of the NCF than the hippocampus-sparing WBRT 
alone.34
Hippocampus sparing-WBRT techniques includ-
ing the volumetric modulated arc technique and 
HT are the most frequently used methods to de-
crease the radiation doses of the hippocampus and 
HHA.35-37 In the study of Fan et al, which was the 
first report of simultaneous hippocampus and HHA 
sparing during PCI, the authors showed that the 
mean hippocampus, hypothalamus, and hypophy-
sis doses might be reduced to 9.6 Gy, 11.06 Gy, and 
10.66 Gy, respectively, lending support to our re-
spective mean doses in our modified plan: 7.1 Gy, 
10.38 Gy and 9.8 Gy.34 In a phase II randomized 
trial, a mean hippocampal dose of ≤ 10 Gy was re-
lated to a 23% improvement in the Hopkins Verbal 
Learning Test compared to previous hippocampus 
sparing-WBRT studies.26 Accordingly, in another 
study, emphasizing its radio-sensitivity, a dose-
dependent hippocampal atrophy (>40 Gy vs <10 
Gy, p= 0.03) was shown to occur on first year MRI 
scans.38 Rong et al analyzed the dosimetric differ-
ences between HT, step and shot intensity modulat-
ed radiotherapy, and rapidarc plans for hippocam-
pus-sparing WBRT. They reported that the mean 
hippocampal doses of Dmax 15.1 Gy and D100% 8.0 
with HT were notably lower than their counterparts 
achieved with other plans which resembled our re-
spective values of 15.7 Gy and 8.1 Gy, achieved 
in 30 Gy of the WBRT plan.39 Although the mean 
Dmax values of the bilateral lens (3.3 Gy vs 3.3 
Gy) and optic chiasm (33.9 Gy vs 28 Gy) were 
similar between the study by Rong and our study, 
those of the optic nerves were considerably lower 
in our study (33.9 Gy vs 13.3 Gy). Regarding the 
mean PTV, D98%, and D2% in the present investiga-
tion (25.9 Gy and 35.0 Gy) were comparable to the 
study of Rong et al (27.5 Gy and 32.2 Gy) despite 
relatively higher HI in our study (0.30 ± 0.07 vs 
0.15 ± 0.03), which indicated inferior dose homo-
geneity due to the incorporation of HHA sparing. 
In a study investigating the effect of inclined and 
neutral head positions on HS-WBRT, the mean 
D100% (10.45 Gy vs 12.07 Gy, p= 0.007) and Dmax 
(13.7 Gy vs 15.7 Gy, p= 0.003) of the hippocampus 
were significantly lower in the inclined position of 
the head.40 Although the D100% values of the hip-
pocampus in both of the positions were higher than 
the value we found (8.1 Gy), the Dmax in the in-
clined position appeared to be more favorable than 
ours (13.7 Gy ± 0.25 vs 15.7 Gy ± 0.8).
In addition to the apparent hormonal deficiency 
risk with > 50 Gy of radiotherapy dose, even 12 
Gy of hypothalamic dose can induce neuro-endo-
crine abnormalities.41,42 The deficiency of growth 
hormone, the most radio-sensitive hypophysial 
hormone, can occur after mean radiotherapy doses 
of 15 Gy43-45, and up to 100% of the patients may 
suffer from endocrine insufficiencies when the ra-
Table 2. Mean doses in 12 patients
Organ Parameter Per protocol Modified protocol
PTV D98% 25.9 ± 0.85 Gy 21.4 ± 0.40 Gy
 D2% 35.0 ± 1.32 Gy 30.5 ± 1.33 Gy
Hippocampus D100% 8.1 ± 0.47 Gy 7.1 ± 0.68 Gy
 Dmax   15.7 ± 0.84 Gy   13.2 ± 1.08 Gy
Hypothalamus Dmean 12.6 ± 0.76 Gy  10.8 ± 1,38 Gy 
Pituitary gland Dmean 11.4 ± 1.22 Gy  9.8 ± 1.50 Gy
Optic chiasm  Dmax  28.0± 6.80 Gy  25.1± 4.42 Gy
Optic nerves Dmax  13.3 ± 3.80 Gy  14.6 ± 3.11 Gy
Lens Dmax   3.5 ± 0.86 Gy   3.2 ± 0.73 Gy
Abbreviations: PTV= planning target volume; D98%= the dose which %98 of the target volume receives;  D2%= the dose which 2% of the target volume 
receives; D100%= minimum dose; Dmax= maximum dose; Dmean= mean dose
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diotherapy doses exceed 30 Gy.46 While growth 
hormone insufficiency risk is reported to be about 
50% following 16 Gy of radiotherapy47, 12 Gy for 
HHA was estimated to be safe.48 Still, the actual in-
cidence of treatment-related hormone insufficiency 
can vary as a result of heterogeneities including the 
presence or extent of surgery, follow-up intervals, 
cut-off laboratory values, definitions of hormone-
insufficiency, and radiotherapy techniques.49-51 In 
this respect, the mean doses of the hypothalamus 
(12.6 Gy) and hypophysis (11.4 Gy) achieved in 
our study were concordant with the recommended 
safer range.
The hippocampal dose constraints for 25 Gy of 
PCI were D100%≤ 7.5 Gy and Dmax≤ 13.3 Gy which 
appeared to be significantly lower than the values 
of  D100%≤ 9 Gy and Dmax≤ 16 Gy, recommended 
in the RTOG 0933 guidelines for the protocol of 30 
Gy of WBRT.26  The rationale to perform further 
modifications for hippocampal dose constraints 
can be the potential intrinsic radiosensitivity vari-
ations of the patients which can also enhance the 
risk of NCF decline even for the cohort receiving 
a relatively lower dose schedule.  Furthermore, be-
cause of the lack of the long-term NCF outcomes 
of RTOG 0933, it can be rational to reduce the 
threshold radiotherapy doses for hippocampi in ac-
cordance with the results of available studies re-
porting better NCF with lower constraints, such as 
<7.3 Gy to 40% of bilateral hippocampi14, a Dmax 
of 9 Gy to 100% of the hippocampi25 and a Dmax 
of 5.83 Gy to 100% of the bilateral hippocampi.52 
In the view of the reasons aforementioned, the use 
of 3HS-WBRT should not be restricted to only the 
adult patients with small-cell lung carcinoma pa-
tients undergoing PCI but also applied to the pedi-
atric cohort who are relatively more vulnerable to 
the effects of radiation compared to the adults.53 
Additionally, the length of survival in patients with 
childhood brain tumors at 70% at 10 years renders 
the further minimization of radiotherapy-related 
neurotoxicity more meaningful than adults with 
a relatively shorter expectation of survival.54 For 
instance, there is an increased dementia effect af-
ter craniospinal irradiation, which was described 
about a half century ago in patients with medul-
loblastoma aged < 2 years.55 This can necessitate 
further maneuvers besides the efforts of decreasing 
the radiotherapy doses or delaying the craniospi-
nal irradiation until 3 years of age. Additionally, 
underlining the importance of sparing of the in-
tracranial endocrine organs the 20-year follow-
up series by Institute Curie demonstrated that the 
endocrine complications were as common as 52% 
in medulloblastoma survivors after craniospinal ir-
radiation.56 Accordingly, 3HS-WBRT appears to be 
rational for conserving NCF. 
Radiation-induced HHA damage can also be a 
source of severe metabolic, social, financial, psy-
chiatric, and educational problems which alto-
gether can negatively influence psychosocial and 
medical status of the patients.57 For instance, HHA-
associated endocrine abnormalities or obesity can 
cause diabetes mellitus, hypertension, dyslipidem-
ia, cardiovascular problems, fertility, and pubertal 
disorders with resultant diminishments in the QoL 
measures and even shortened life spans.57 Consid-
ering the educational outcomes, compared to those 
children treated with intravenous/intrathecal meth-
otrexate alone, the combination of chemotherapy 
with PCI has been shown to cause significantly 
more severe declines in the achievement, intelli-
gence and attention tasks, and therefore the school 
success in survivors of acute lymphoblastic leuke-
mia.58,59 Additionally, recent data indicated that un-
employment was reported to be 5 times higher in 
brain tumor survivors, associated with the primary 
tumor and related treatments.57 All these adverse 
effects of whole- or partial brain radiotherapy men-
tioned above support our current efforts to achieve 
3HS-WBRT or 3HS-partial brain radiotherapy and 
appear to be an important step in minimizing the 
social, financial, psychiatric, and educational bur-
den due to impaired HHA.
The present study is the second in the literature to 
investigate 3HS-WBRT to the best of our knowl-
edge. In addition to available dose constraints for 
30 Gy of WBRT, we also recommend an alterna-
tive reduced dose schedule of 1 in 6 of the original 
which can provide a further protection for the co-
hort who can be more sensitive to radiation.  On the 
other hand, although the delineation of hippocam-
pus and HHA was performed according to the ac-
cessible guidelines and atlases, the lack of a neuro-
radiologist in the study may potentially weaken the 
accuracy of the 3H contouring process. Despite the 
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main goal of the study to research the feasibility of 
HHA as well as the hippocampus, the interconnec-
tions between hypothalamus and hypophysis were 
not included in the sparing volume, which can de-
crease the reliability of the 3HS-WBRT. Although 
the mean treatment time was reported to be 15.93 
and 20.18 minutes in a dosimetric study evaluat-
ing the feasibility of hippocampus sparing-PCI and 
-WBRT, respectively, the relatively longer treat-
ment time of 31.8 minutes elapsed during 3HS-
WBRT can be questionable in cases requiring an-
esthesia during the treatment process.60
In conclusion, as a consequence of improved sur-
vival rates of the patients with cancer requiring 
whole brain or partial brain radiotherapy during the 
course of disease, the maintenance of neurocogni-
tive and neuroendocrine functions, as the predic-
tors of QoL, has become one of the main goals as 
well as disease control in the brain. In this context, 
this study demonstrated the feasibility of 3HS-
WBRT with HT taking into account the suggested 
dose constraints in the literature. Considering the 
fact that a technique investigation can be more 
valuable for what it offers in practice, prospective 
studies evaluating the baseline and follow-up ob-
jective measurements for 3H can be required for 
precise deductions.
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